분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-08-07 23:26:03 , Hit : 716
 Resistance to HIV Engineered Via CRISPR

The Scientist »
News & Opinion »
Daily News

Mice transplanted with human hematopoietic stem cells that have an HIV receptor gene, CCR5, disrupted by gene editing allows the animals to ward off HIV infection.

By Anna Azvolinsky | August 3, 2017

http://www.the-scientist.com/?articles.view/articleNo/50018/title/Resistance-to-HIV-Engineered-Via-CRISPR/&utm_campaign=NEWSLETTER_TS_The-Scientist-Daily_2016&utm_source=hs_email&utm_medium=email&utm_content=55018669&_hsenc=p2ANqtz-9JBWKmxdQbqY3kAgsFu3PhFu_lFPXFdKEMtaP8J5GS2BDbyWi57GhwqjAJOIYbA5gZxBvJzXck6W_LORkTn0Bc83VePQ&_hsmi=55018669


A minor proportion of people harbor a homozygous mutation in CCR5—a gene that encodes a receptor found on immune cells—that thwarts HIV’s attempts to get inside the cells. In an attempt to mimic this natural resistance, researchers mutated CCR5 in human fetal liver hematopoietic stem/progenitor cells (HSPCs) and showed that the cells could block HIV infection after transplantation into mice.

“These are expected observations that support prior data that targeting CCR5 can impede HIV replication and spread,” says neuroscientist Kamel Khalili who studies HIV infection at Temple University’s Lewis Katz School of Medicine in Philadelphia and who was not involved in the study. “CRISPR may be more convenient for gene editing than the prior gene editing tools used.”

The study is not the first to use gene editing to interrupt the CCR5 gene in human hematopoietic stem/progenitor cells. In a study published in 2010, Paula Cannon and her colleagues used zinc-finger nucleases to disrupt the gene and showed that the edited cells, when engrafted into mice, could clonally expand and retain the CCR5 deletion. This previous work has led to an on-going clinical trial to test this gene editing approach in HIV-infected individuals.  

With CRISPR, Khalili’s team previously cut out HIV from the human genome, yet there are also studies of how HIV could evade CRISPR-based anti-HIV therapy. There is yet no CRISPR-based gene editing system being tested in clinical trials in the United States.

See “How HIV Can Escape an Experimental CRISPR Therapy”

In the new work, published August 2 in Molecular Therapy, Hu Chen of the 307 Hospital of the Peoples Liberation Army, Hongkui Deng of the Peking University Stem Cell Research Center, both in Beijing, China, and their colleagues used CRISPR/Cas9 to disrupt CCR5 in CD34+ HSPCs. They demonstrated a 21 percent to 28 percent CCR5 editing efficiency, higher than the 17 percent efficiency reported using the zinc finger approach.

The work is the first to use CRISPR to achieve a long-lasting CCR5 mutation in HSCs in an animal model. “One of the advantages of CRISPR is its high efficiency on difficult to transfect cells,” write Deng and Chen in a joint email to The Scientist.


CCR5 seems to be the one Achilles heel of HIV. There may be some other targets but for now it’s the best target.—James Riley,
University of Pennsylvania

The authors were able to target a region of CCR5 that had significant differences with CCR2, a highly homologous gene subject to off-target effects using the zinc finger nuclease approach, notes James Riley, who studies how HIV infects T-cells at the University of Pennsylvania and who was not involved in the current study.    

The team showed that these CRISPR-edited HSPCs could be successfully engrafted into mice and that the cells could differentiate to form the spectrum of normal immune cell lineages over the course of 47 weeks. The CCR5-edited HSPCs from the engrafted mice could then be used for a secondary transplantation into another set of mice, the researchers showed.

“The long-term reconstitution and secondary transplantation were time-consuming. It took us more than one-year monitoring of the mice to confirm the gene editing is robust in long-term HSCs,” write Deng and Chen.

See “Genome Editing Cuts Out HIV”

Next, the researchers challenged either mice transplanted with CCR5-edited or non-edited human CD34+ HSPCs with an HIV strain that uses CCR5 to gain access to T-cells. In the mice harboring the mutated human stem cells, there was a decrease in HIV RNA in the first few weeks of infection and a smaller decline in CD4+ T-cells compared to animals transplanted with normal human HSPCs.  

“This is convincing evidence that CRISPR mediated deletion of CCR5 results in the intended resistance to the CD4+ progeny of the CCR5,” writes David DiGiusto, who directs Stanford University’s Laboratory for Cell and Gene Medicine and has helped development of the zinc finger approach for disrupting CCR5, in an email to The Scientist.

Still, it is unlikely that fetal liver stem cells will be used in human clinical trials, DiGiusto and Khalili agree. “Caution should be taken interpreting [these results] as generalizable to HSPCs from adult HIV patients,” writes DiGiusto.

A caveat to targeting CCR5, notes Khalili, is that this approach “may not be a complete cure because the virus itself is not eliminated and may shift to using the CCR4 or another receptor to spread.” Targeting CCR5 will also not protect against X4 tropic HIV isolates that use the CXCR4 receptor, rather than CCR5, to gain entry into immune cells.

Yet “CCR5 seems to be the one Achilles heel of HIV. There may be some other targets but for now it’s the best target,” says Riley.

Chen, Deng, and their colleagues are planning to start a clinical trial to test whether CRISPR/Cas9-mutated CCR5 in donor CD34+ hematopoietic stem/progenitor cells can be safely infused into HIV-infected individuals and could confer a level of resistance to HIV.

Writes DiGiusto, “the ongoing clinical trials that have been developed will begin to answer the feasibility and efficacy of targeting CCR5 for HIV infection.”

L. Xu et al., “CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo,” Molecular Therapy, doi.org/10.1016/j.ymthe.2017.04.027, 2017.







1027   UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 695
1026   “유전자 치료 법률 금지 한국 유일” vs “생명체 설계도 바꾸는 건 문제”  이성욱 2017/08/28 730
1025   Cancer Onset May Be Caused by Immune System Fighting Viruses  이성욱 2017/08/25 716
1024   유전자 가위로 바이러스 제거한 '청정 돼지' 나왔다  이성욱 2017/08/24 763
1023   CRISPR Corrects RNA-based Disease Defects  이성욱 2017/08/14 735
1022   Uncovering Functions of Circular RNAs  이성욱 2017/08/14 721
1021   First In Vivo Function Found for Animal Circular RNA  이성욱 2017/08/14 767
1020   Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
  Resistance to HIV Engineered Via CRISPR  이성욱 2017/08/07 716
1018   [바이오토픽] 드디어 올 것이 왔다: CRISPR, 생존가능 인간배아의 질병초래 유전자 교정 성공  이성욱 2017/08/03 730
1017   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 781
1016   A Novel Mammalian Genomic Imprinting Mechanism  이성욱 2017/07/25 812
1015   Mammalian Immunity: What’s RNAi Got to Do with It?  이성욱 2017/07/25 704
1014   CRISPR Structure Data Reveal How Cas Enzymes Choose Target  이성욱 2017/07/25 1088
1013   Anti-CRISPR Protein Reduces Off-Target Effects  이성욱 2017/07/14 792
1012   CRISPR Encodes Movie into Bacteria, Then DNA Sequencing Plays It  이성욱 2017/07/14 1018
1011   [바이오토픽] CRISPR를 이용하여 세균의 DNA에 영화를 저장!  이성욱 2017/07/14 864
1010   [바이오토픽] FDA 자문위원회, CAR-T(chimeric antigen receptor T cell) 승인 만장일치로 권고  이성욱 2017/07/14 748
1009   유전자치료제 '인보사' 연골재생 입증못해도 허가받은 까닭  이성욱 2017/07/14 744
1008   코오롱 인보사허가  이성욱 2017/07/12 704

[이전 10개] [1]..[11][12] 13 [14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN